TIXiMED is developing TIX100, a first-of-its-kind oral therapeutic that inhibits TXNIP, as a treatment for Type 1 and Type 2 Diabetes, as well as metabolic dysfunction–associated steatotic liver disease (MASLD). The company has successfully completed a Phase 1 clinical study of TIX100 in human subjects. TIX100 is an orally administered novel chemical entity that has shown efficacy in preclinical models and aims to address the underlying causes of diabetes without causing hypoglycemia or weight gain.